In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug.
Administration, Inhalation
Aerosols
Animals
Drug Compounding
/ methods
Drug Delivery Systems
Excipients
Hydrocarbons, Fluorinated
/ administration & dosage
Metered Dose Inhalers
/ microbiology
Migraine Disorders
/ drug therapy
Oxazolidinones
/ administration & dosage
Particle Size
Rats
Tryptamines
/ administration & dosage
Anti-migraine
HFA propellant
metered dose inhaler
next generation impactor
zolmitriptan
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
Enhancement of zolmitriptan bioavailability through development of micronized zolmitriptan pressurized metered dose inhaler (MDI) as an alternative to its traditional drug delivery systems. A reversed phase HPLC method for zolmitriptan determination was developed and evaluated. Micronized zolmitriptan MDI formulations were prepared using two different propellants. The prepared formulations were evaluated for mean shot weight, drug content, and leakage rate in addition to in-vitro deposition using next generation impactor where mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), fine particle dose, fine particle fraction (FPF), emitted dose (ED), and dispersibility were determined. The selected formulation was evaluated for in-vivo bronchial absorption in rats. The physicochemical characters of the prepared formulations were found to be dependent mainly on the vapor pressure of the used propellant. MDI formulation prepared with HFA 134a propellant was found to have the lowest MMAD (3.47 ± 0.65) with GSD of 2.3 ± 0.4. It also had the highest FPF (41.9), ED (89.26 ± 2.35) with dispersibility of 46.9%. This formulation, when applied to rats, resulted in faster
Identifiants
pubmed: 31274014
doi: 10.1080/10717544.2019.1618419
pmc: PMC6691845
doi:
Substances chimiques
Aerosols
0
Excipients
0
Hydrocarbons, Fluorinated
0
Oxazolidinones
0
Tryptamines
0
zolmitriptan
2FS66TH3YW
norflurane
DH9E53K1Y8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-699Références
Pharm Dev Technol. 2000;5(2):153-62
pubmed: 10810745
J Aerosol Med. 2001;14 Suppl 1:S19-26
pubmed: 11424889
J Aerosol Med. 2001 Summer;14(2):255-66
pubmed: 11681657
Adv Drug Deliv Rev. 2003 Jul 18;55(7):807-28
pubmed: 12842602
J Pharm Pharm Sci. 2003 May-Aug;6(2):252-73
pubmed: 12935438
Pharm Res. 2004 Jan;21(1):127-35
pubmed: 14984267
Neurology. 2004 Mar 23;62(6):883-7
pubmed: 15037686
J Allergy Clin Immunol. 2004 Nov;114(5):1027-32
pubmed: 15536405
Cephalalgia. 2004;24 Suppl 2:8-15
pubmed: 15595989
Respir Care. 2005 Sep;50(9):1177-90
pubmed: 16122401
J Drug Target. 2005 Jun;13(5):317-24
pubmed: 16199375
Headache. 2006 Jan;46(1):138-49
pubmed: 16412161
J Pharm Sci. 2006 Nov;95(11):2438-51
pubmed: 16886198
Arch Neurol. 2006 Nov;63(11):1537-42
pubmed: 16966497
J Control Release. 2006 Oct 27;115(3):289-97
pubmed: 17023085
Nat Rev Drug Discov. 2007 Jan;6(1):67-74
pubmed: 17195033
J Pharm Sci. 2008 Mar;97(3):1213-23
pubmed: 17828746
Headache. 2007 Nov-Dec;47(10):1443-6
pubmed: 17868348
AAPS PharmSciTech. 2009;10(1):129-37
pubmed: 19189220
J Aerosol Med Pulm Drug Deliv. 2009 Mar;22(1):19-28
pubmed: 19392586
Int J Pharm. 2010 Jun 15;392(1-2):1-19
pubmed: 20223286
Biopharm Drug Dispos. 2010 Mar;31(2-3):189-201
pubmed: 20238376
J Pharm Sci. 2010 Nov;99(11):4554-64
pubmed: 20845454
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S59-69
pubmed: 21133801
J Control Release. 2012 Feb 10;157(3):383-90
pubmed: 21864592
Acta Diabetol. 2012 Aug;49(4):315-25
pubmed: 22124766
Lung India. 2012 Jan;29(1):44-9
pubmed: 22345913
Chem Pharm Bull (Tokyo). 2012;60(5):593-7
pubmed: 22689396
J Control Release. 2012 Sep 10;162(2):310-20
pubmed: 22800582
Expert Opin Pharmacother. 2012 Sep;13(13):1961-8
pubmed: 22860628
Indian J Pharm Sci. 2011 Sep;73(5):543-9
pubmed: 22923867
Drug Dev Ind Pharm. 2013 Mar;39(3):413-24
pubmed: 23216244
J Pharm Sci. 2013 Apr;102(4):1165-72
pubmed: 23381932
Int J Pharm. 2013 May 1;448(1):9-18
pubmed: 23518364
Eur J Pharm Sci. 2013 Aug 16;49(5):805-18
pubmed: 23797056
Drug Deliv. 2014 Mar;21(2):75-86
pubmed: 24102636
AAPS PharmSciTech. 2014 Apr;15(2):326-38
pubmed: 24357110
AAPS PharmSciTech. 2014 Apr;15(2):434-55
pubmed: 24452499
Comput Biol Med. 2014 Nov;54:145-55
pubmed: 25243888
Pharm Dev Technol. 2015 Dec;20(8):897-910
pubmed: 25243986
Int J Pharm Compd. 2014 Jul-Aug;18(4):305-10
pubmed: 25474859
Expert Opin Drug Deliv. 2015;12(10):1661-75
pubmed: 26067386
Int J Pharm. 2016 Mar 30;501(1-2):124-38
pubmed: 26836711
Adv Pharm Bull. 2016 Mar;6(1):57-64
pubmed: 27123418
J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:306-12
pubmed: 27126304
Expert Opin Pharmacother. 2016 Sep;17(13):1733-43
pubmed: 27416108
Int J Pharm. 2017 Aug 30;529(1-2):667-677
pubmed: 28729175
Ther Deliv. 2017 Dec;8(12):1051-1061
pubmed: 29125064